Epoxyeicosatrienoic acid pathway in human health and diseases

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 3, 2013, Pages 188-196

  Bellien, Jeremy ^a,b   Joannides, Robinson ^a,b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF ROUEN   (France)

Author keywords

cardiovascular diseases; endothelium derived hyperpolarization; epoxyeicosatrienoic acids; soluble epoxide hydrolase

Indexed keywords

ARACHIDONIC ACID; CARDIOVASCULAR AGENT; CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 2C9; CYTOCHROME P450 2J2; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE INHIBITOR; EPOXYICOSATRIENOIC ACID; OXIDOREDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ARTERY RESISTANCE; ARTERY TONE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; GAP JUNCTION; HUMAN; HYDRATION; HYPERTENSION; LIPID METABOLISM; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASODILATATION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CORONARY ARTERY DISEASE; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; HYPERTENSION; VASCULAR RESISTANCE;

EID: 84875222009     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318273b007     Document Type: Article

References (88)

1. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res. 2000;41:163-181.
2. Fleming I, Michaelis UR, Bredenkötter D, et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res. 2001;88:44-51.
3. Zeldin DC, Wei S, Falck JR, et al. Metabolism of epoxyeicosatrienoic acids by cytosolic epoxide hydrolase: substrate structural determinants of asymmetric catalysis. Arch Biochem Biophys. 1995;316:443-451.
4. Campbell WB, Deeter C, Gauthier KM, et al. 14,15-Dihydroxyeicosatrienoic acid relaxes bovine coronary arteries by activation of K(Ca) channels. Am J Physiol Heart Circ Physiol. 2002;282:H1656-H1664.
5. Bellien J, Joannides R, Richard V, et al. Modulation of cytochromederived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases? Pharmacol Ther. 2011;131:1-17.
6. Chen Y, Falck JR, Manthati VL, et al. 20-Iodo-14,15-epoxyeicosa-8(Z)- enoyl-3-azidophenylsulfonamide: photoaffinity labeling of a 14,15- epoxyeicosatrienoic acid receptor. Biochemistry. 2011;50:3840-3848.
7. Edwards G, Félétou M, Weston AH. Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pflugers Arch. 2010; 459:863-879.
8. Archer SL, Gragasin FS, Wu X, et al. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation. 2003;107:769-776.
9. Huang A, Sun D, Jacobson A, et al. Epoxyeicosatrienoic acids are released to mediate shear stress-dependent hyperpolarization of arteriolar smooth muscle. Circ Res. 2005;96:376-383.
10. Fleming I, Rueben A, Popp R, et al. Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27:2612-2618.
11. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285: 1276-1279.
12. Krötz F, Riexinger T, Buerkle MA, et al. Membrane-potential- dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol. 2004;24:595-600.
13. Node K, Ruan XL, Dai J, et al. Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem. 2001;276:15983-15989.
14. Ng VY, Morisseau C, Falck JR, et al. Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. Arterioscler Thromb Vasc Biol. 2006;26:2462-2468.
15. Fleming I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat. 2007;82:60-67.
16. Lorthioir A, Guerrot D, Joannides R, et al. Diabetic CVD - Soluble epoxide hydrolase as a target. Cardiovasc Hematol Agents Med Chem. 2012;10:212-222.
17. Fischer D, Landmesser U, Spiekermann S, et al. Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure. Eur J Heart Fail. 2007;9:770-775.
18. Passauer J, Büssemaker E, Lässig G, et al. Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole. Clin Sci (Lond). 2003;105:513-518.
19. Ozkor MA, Murrow JR, Rahman AM, et al. Endothelium-derived hyperpolarizing factor determines resting and stimulated forearm vasodilator tone in health and in disease. Circulation. 2011;123:2244-2253.
20. Halcox JP, Narayanan S, Cramer-Joyce L, et al. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am J Physiol Heart Circ Physiol. 2001;280:H2470-H2477.
21. Taddei S, Versari D, Cipriano A, et al. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J Am Coll Cardiol. 2006;48:508-515.
22. Hillig T, Krustrup P, Fleming I, et al. Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J Physiol. 2003;546:307-314.
23. Buus NH, Simonsen U, Pilegaard HK, et al. Nitric oxide, prostanoid and non-NO, non-prostanoid involvement in acetylcholine relaxation of isolated human small arteries. Br J Pharmacol. 2000;29:184-192.
24. Coats P, Johnston F, MacDonald J, et al. Endothelium-derived hyperpolarizing factor: identification and mechanisms of action in human subcutaneous resistance arteries. Circulation. 2001;103:1702-1708.
25. Brunt VE, Minson CT. KCa channels and epoxyeicosatrienoic acids: major contributors to thermal hyperaemia in human skin. J Physiol. 2012;590:3523-3534.
26. Lenasi H. The role of nitric oxide- and prostacyclin-independent vasodilatation in the human cutaneous microcirculation: effect of cytochrome P450 2C9 inhibition. Clin Physiol Funct Imaging. 2009;29:263-270.
27. Batenburg WW, Garrelds IM, van Kats JP, et al. Mediators of bradykinininduced vasorelaxation in human coronary microarteries. Hypertension. 2004; 43:488-492.
28. Larsen BT, Gutterman DD, Sato A, et al. Hydrogen peroxide inhibits cytochrome p450 epoxygenases: interaction between two endotheliumderived hyperpolarizing factors. Circ Res. 2008;102:59-67.
29. Miura H, Wachtel RE, Liu Y, et al. Flow-induced dilation of human coronary arterioles: important role of Ca(2+)-activated K(+) channels. Circulation. 2001;103:1992-1998.
30. Urakami-Harasawa L, Shimokawa H, Nakashima M, et al. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest. 1997;100:2793-2799.
31. Matoba T, Shimokawa H, Kubota H, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Commun. 2002;290:909-913.
32. Büssemaker E, Popp R, Binder J, et al. Characterization of the endotheliumderived hyperpolarizing factor (EDHF) response in the human interlobar artery. Kidney Int. 2003;63:1749-1755.
33. Hamilton CA, Williams R, Pathi V, et al. Pharmacological characterisation of endothelium-dependent relaxation in human radial artery: comparison with internal thoracic artery. Cardiovasc Res. 1999;42:214-223.
34. Bellien J, Joannides R, Iacob M, et al. Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans. Am J Physiol Heart Circ Physiol. 2006;290: H1347-H1352.
35. Bellien J, Iacob M, Gutierrez L, et al. Crucial role of NO and endotheliumderived hyperpolarizing factor in human sustained conduit artery flowmediated dilatation. Hypertension. 2006;48:1088-1094.
36. Bellien J, Iacob M, Remy-Jouet I, et al. Epoxyeicosatrienoic acids contribute with altered NO and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension. Circulation. 2012; 125:1266-1275.
37. Arnold C, Konkel A, Fischer R, et al. Cytochrome P450-dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol Rep. 2010;62:536-547.
38. Oyekan AO, Youseff T, Fulton D, et al. Renal cytochrome P450 omegahydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J Clin Invest. 1999;104:1131-1137.
39. Giannarelli C, Virdis A, De Negri F, et al. Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients. Circulation. 2009;119:1625-1633.
40. Lee CR, Pretorius M, Schuck RN, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans. Hypertension. 2011;57:116-122.
41. Ohlmann P, Martínez MC, Schneider F, et al. Characterization of endothelium-derived relaxing factors released by bradykinin in human resistance arteries. Br J Pharmacol. 1997;121:657-664.
42. Bellien J, Favre J, Iacob M, et al. Arterial stiffness is regulated by nitric oxide and endothelium-derived hyperpolarizing factor during changes in blood flow in humans. Hypertension. 2010;55:674-680.
43. Shiode N, Morishima N, Nakayama K, et al. Flow-mediated vasodilation of human epicardial coronary arteries: effect of inhibition of nitric oxide synthesis. J Am Coll Cardiol. 1996;27:304-310.
44. Catella F, Lawson JA, Fitzgerald DJ, et al. Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancyinduced hypertension. Proc Natl Acad Sci U S A. 1990;87:5893-5897.
45. Minuz P, Jiang H, Fava C, et al. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension. 2008;51:1379-1385.
46. Büssemaker E, Popp R, Fisslthaler B, et al. Aged spontaneously hypertensive rats exhibit a selective loss of EDHF-mediated relaxation in the renal artery. Hypertension. 2003;42:562-568.
47. Zordoky BN, El-Kadi AO. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther. 2010;125:446-463.
48. Dreisbach AW, Japa S, Sigel A, et al. The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens. 2005;18:1276-1281.
49. Kullmann S, Binner P, Rackebrandt K, et al. Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention. BMC Cardiovasc Disord. 2009;9:48.
50. Yu BN, Luo CH, Wang D, et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta. 2004;348: 57-61.
51. King LM, Gainer JV, David GL, et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics. 2005;15:7-13.
52. Polonikov AV, Ivanov VP, Solodilova MA, et al. A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population. Dis Markers. 2008;24:119-126.
53. Theken KN, Schuck RN, Edin ML, et al. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis. 2012;222:530-536.
54. Fichtlscherer S, Dimmeler S, Breuer S, et al. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation. 2004;109: 178-183.
55. Chen M, Liu XJ, Yan SD, et al. Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease. Atherosclerosis. 2012;220:168-171.
56. Ward NC, Croft KD, Blacker D, et al. Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls. Clin Sci (Lond). 2011;121:501-507.
57. Monti J, Fischer J, Paskas S, et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet. 2008;40:529-537.
58. Mullen MJ, Kharbanda RK, Cross J, et al. Heterogenous nature of flowmediated dilatation in human conduit arteries in vivo. Relevance to endothelial dysfunction in hypercholesterolemia. Circ Res. 2001;88:145-151.
59. Krummen S, Drouin A, Gendron ME, et al. ROS-sensitive cytochrome P450 activity maintains endothelial dilatation in ageing but is transitory in dyslipidaemic mice. Br J Pharmacol. 2006;147:897-904.
60. Donato AJ, Eskurza I, Jablonski KL, et al. Cytochrome P-450 2C9 signaling does not contribute to age-associated vascular endothelial dysfunction in humans. J Appl Physiol. 2008;105:1359-1363.
61. Passauer J, Pistrosch F, Lässig G, et al. Nitric oxide- and EDHF-mediated arteriolar tone in uremia is unaffected by selective inhibition of vascular cytochrome P450 2C9. Kidney Int. 2005;67:1907-1912.
62. Lee CR, Imig JD, Edin ML, et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 2010;24:3770-3781.
63. Xu X, Zhao CX, Wang L, et al. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes. 2010; 59:997-1005.
64. Chen G, Wang P, Zhao G, et al. Cytochrome P450 epoxygenase CYP2J2 attenuates nephropathy in streptozotocin-induced diabetic mice. Prostaglandins Other Lipid Mediat. 2011;96:63-71.
65. Edin ML, Wang Z, Bradbury JA, et al. Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. FASEB J. 2011; 25:3436-3447.
66. Fisslthaler B, Michaelis UR, Randriamboavonjy V, et al. Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression. Biochim Biophys Acta. 2003;1619:332-339.
67. Zhao X, Quigley JE, Yuan J, et al. PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am J Physiol Heart Circ Physiol. 2006;290:H2187-H2195.
68. Rettie AE, Jones JP. Clinical and Toxicological Relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol. 2005;45:477-494.
69. Sudhahar V, Shaw S, Imig JD. Epoxyeicosatrienoic acid analogs and vascular function. Curr Med Chem. 2010;17:1181-1190.
70. Yu Z, Xu F, Huse LM, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res. 2000; 87:992-998.
71. Imig JD, Zhao X, Capdevila JH, et al. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002;39:690-694.
72. Zhao X, Yamamoto T, Newman JW, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol. 2004;15:1244-1253.
73. Ai D, Pang W, Li N, et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A. 2009;106:564-569.
74. Gao J, Bellien J, Gomez E, et al. Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension. J Hypertens. 2011;29:1128-1135.
75. Luo P, Chang HH, Zhou Y, et al. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther. 2010;334: 430-438.
76. Luria A, Bettaieb A, Xi Y, et al. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A. 2011;108:9038-9043.
77. Elmarakby AA, Faulkner J, Al-Shabrawey M, et al. Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. Am J Physiol Regul Integr Comp Physiol. 2011;301:R1307-R1317.
78. Motoki A, Merkel MJ, Packwood WH, et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemiareperfusion injury in vivo. Am J Physiol Heart Circ Physiol. 2008;295: H2128-H2134.
79. Merabet N, Bellien J, Glevarec E, et al. Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure. J Mol Cell Cardiol. 2012;52:660-666.
80. Zhang LN, Vincelette J, Cheng Y, et al. Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler Thromb Vasc Biol. 2009;29:1265- 1270.
81. Chen D, Whitcomb R, MacIntyre E, et al. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in singleand multiple-dose studies in healthy human subjects. J Clin Pharmacol. 2012;52:319-328.
82. Falck JR, Kodela R, Manne R, et al. 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. J Med Chem. 2009;52:5069-5075.
83. Loot AE, Fleming I. Cytochrome P450-derived epoxyeicosatrienoic acids and pulmonary hypertension: central role of transient receptor potential C6 channels. J Cardiovasc Pharmacol. 2011;57:140-147.
84. Keserü B, Barbosa-Sicard E, Schermuly RT, et al. Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition. Cardiovasc Res. 2010;85:232-240.
85. Panigrahy D, Greene ER, Pozzi A, et al. EET signaling in cancer. Cancer Metastasis Rev. 2011;30:525-540.
86. Panigrahy D, Edin ML, Lee CR, et al. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest. 2012;122:178-191.
87. Jung O, Jansen F, Mieth A, et al. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One. 2010;5:e11979.
88. Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002;40:505-510.